95TH GENERAL ASSEMBLY
State of Illinois
2007 and 2008
SB0648

 

Introduced 2/8/2007, by Sen. Carol Ronen

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 15/2   from Ch. 111, par. 5352
225 ILCS 15/5.1 new
225 ILCS 15/5.2 new
225 ILCS 15/5.3 new
225 ILCS 15/5.4 new
225 ILCS 15/5.5 new
225 ILCS 15/5.6 new
225 ILCS 15/15   from Ch. 111, par. 5365
225 ILCS 65/5-10
225 ILCS 85/3   from Ch. 111, par. 4123
225 ILCS 85/4   from Ch. 111, par. 4124
720 ILCS 570/102   from Ch. 56 1/2, par. 1102

    Amends the Clinical Psychologist Licensing Act to include the certification of prescribing clinical psychologists. Provides that the Department of Financial and Professional Regulation shall certify licensed, doctoral-level psychologists to prescribe and dispense drugs in accordance with applicable State and federal laws. Sets forth application and renewal requirements, prescribing practices, controlled substance compliance requirements, and requirements concerning interaction with the State Board of Pharmacy of the Department, as the areas relate to prescribing clinical psychologists and prescriptive authority. Grants certain rulemaking authority to the Clinical Psychologist Licensing and Disciplinary Board. Makes other changes. Amends the Nursing and Advanced Practice Nursing Act, the Pharmacy Practice Act of 1987, and the Illinois Controlled Substances Act to make corresponding changes.


LRB095 06496 RAS 26597 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

SB0648 LRB095 06496 RAS 26597 b

1     AN ACT concerning regulation.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 5. The Clinical Psychologist Licensing Act is
5 amended by changing Sections 2 and 15 and by adding Sections
6 5.1, 5.2, 5.3, 5.4, 5.5, and 5.6 as follows:
 
7     (225 ILCS 15/2)  (from Ch. 111, par. 5352)
8     (Section scheduled to be repealed on January 1, 2017)
9     Sec. 2. Definitions. As used in this Act:
10         (1) "Department" means the Department of Financial and
11     Professional Regulation.
12         (2) "Secretary" means the Secretary of Financial and
13     Professional Regulation.
14         (3) "Board" means the Clinical Psychologists Licensing
15     and Disciplinary Board appointed by the Secretary.
16         (4) "Person" means an individual, association,
17     partnership or corporation.
18         (5) "Clinical psychology" means the independent
19     evaluation, classification and treatment of mental,
20     emotional, behavioral or nervous disorders or conditions,
21     developmental disabilities, alcoholism and substance
22     abuse, disorders of habit or conduct, the psychological
23     aspects of physical illness. The practice of clinical

 

 

SB0648 - 2 - LRB095 06496 RAS 26597 b

1     psychology includes psychoeducational evaluation, therapy,
2     remediation and consultation, the use of psychological and
3     neuropsychological testing, assessment, psychotherapy,
4     psychoanalysis, hypnosis, biofeedback, and behavioral
5     modification when any of these are used for the purpose of
6     preventing or eliminating psychopathology, or for the
7     amelioration of psychological disorders of individuals or
8     groups. "Clinical psychology" does not include the use of
9     hypnosis by unlicensed persons pursuant to Section 3.
10         (6) A person represents himself to be a "clinical
11     psychologist" within the meaning of this Act when he or she
12     holds himself out to the public by any title or description
13     of services incorporating the words "psychological",
14     "psychologic", "psychologist", "psychology", or "clinical
15     psychologist" or under such title or description offers to
16     render or renders clinical psychological services as
17     defined in paragraph (7) of this Section to individuals,
18     corporations, or the public for remuneration.
19         (7) "Clinical psychological services" refers to any
20     services under paragraph (5) of this Section if the words
21     "psychological", "psychologic", "psychologist",
22     "psychology" or "clinical psychologist" are used to
23     describe such services by the person or organization
24     offering to render or rendering them.
25         (8) "Drugs" shall have the same meaning as that term is
26     given in the Pharmacy Practice Act of 1987.

 

 

SB0648 - 3 - LRB095 06496 RAS 26597 b

1         (9) "Medicines" shall have the same meaning as that
2     term is given in the Pharmacy Practice Act of 1987.
3         (10) "Prescription" means an order for a drug,
4     laboratory test, or any medicines, devices, or treatments,
5     including controlled substances, as defined by State law.
6         (11) "Prescriptive authority" means the authority to
7     prescribe and dispense drugs, medicines, or other
8     treatment procedures.
9         (12) "Prescribing clinical psychologist" means a
10     licensed, doctoral-level psychologist who has undergone
11     specialized training, has passed an examination accepted
12     by the Clinical Psychologist Licensing and Disciplinary
13     Board, and has a current certificate granting prescriptive
14     authority issued by the Department that has not been
15     revoked or suspended.
16     This Act shall not apply to persons lawfully carrying on
17 their particular profession or business under any valid
18 existing regulatory Act of the State.
19 (Source: P.A. 94-870, eff. 6-16-06.)
 
20     (225 ILCS 15/5.1 new)
21     (Section scheduled to be repealed on January 1, 2017)
22     Sec. 5.1. Certification to prescribe drugs. The Department
23 shall certify licensed, doctoral-level psychologists to
24 prescribe and dispense drugs in accordance with applicable
25 State and federal laws. The Board shall develop and implement

 

 

SB0648 - 4 - LRB095 06496 RAS 26597 b

1 procedures for reviewing educational and training credentials
2 for that certification process in accordance with current
3 standards of professional practice. The Board may seek the
4 advice of other State agencies with relevant experience in
5 devising the certification procedures and criteria.
 
6     (225 ILCS 15/5.2 new)
7     (Section scheduled to be repealed on January 1, 2017)
8     Sec. 5.2. Application requirements for prescriptive
9 authority.
10     (a) The Department shall grant certification to a
11 psychologist who applies for prescriptive authority and
12 demonstrates by official transcript or other official evidence
13 satisfactory to the Board all of the following:
14         (1) that he or she has completed a doctoral program in
15     psychology from a regionally-accredited university or
16     professional school or, if the program is not accredited at
17     the time of graduation, that he or she has completed a
18     doctoral program in psychology that meets recognized
19     acceptable professional standards, as determined by the
20     Board;
21         (2) that he or she holds a current license to practice
22     psychology in Illinois;
23         (3) that he or she has completed an organized program
24     of intensive didactic instruction, as defined by the Board,
25     within the 5-year period immediately before the date of

 

 

SB0648 - 5 - LRB095 06496 RAS 26597 b

1     application, consisting of a minimum of 300 contact hours
2     and consisting of the following core areas of instruction:
3     (i) neuroscience, (ii) pharmacology, (iii)
4     psychopharmacology, (iv) physiology, (v) pathophysiology,
5     (vi) appropriate and relevant physical and laboratory
6     assessment, and (vii) clinical pharmacotherapeutics;
7         (4) that he or she has obtained supervised and relevant
8     clinical experience sufficient to achieve competency in
9     the treatment of a diverse patient population under the
10     direction of qualified practitioners, as determined by the
11     Board, within the 5-year period immediately preceding the
12     date of application that includes the pharmacological
13     treatment of a minimum of 100 patients under the full
14     supervision and control of a designated qualified
15     practitioner, who will then certify the clinical
16     competency of the candidate for certification; and
17         (5) that he or she has passed a certifying examination
18     stipulated by the Board.
19     (b) If the applicant completed the organized program of
20 intensive didactic instruction required by paragraph (3) of
21 subsection (a) more than 5 years prior to application, the
22 Department shall grant the certification for prescriptive
23 authority if the applicant has met the requirements specified
24 in paragraphs (1), (2), (4), and (5) of subsection (a) and has
25 completed 24 hours of continuing education in the 2 years
26 immediately prior to application as specified in Section 5.3.
 

 

 

SB0648 - 6 - LRB095 06496 RAS 26597 b

1     (225 ILCS 15/5.3 new)
2     (Section scheduled to be repealed on January 1, 2017)
3     Sec. 5.3. Renewal of prescriptive authority; prescriptive
4 authority continuing education.
5     (a) The Board shall establish, by rule, a method for the
6 annual renewal of prescriptive authority at the time of, or in
7 conjunction with, the renewal of clinical psychology licenses.
8     (b) Each applicant for renewal of prescriptive authority
9 shall present to the Board satisfactory evidence that
10 demonstrates the completion of 24 hours of instruction relevant
11 to prescriptive authority during the 2 years immediately prior
12 to his or her application for renewal.
 
13     (225 ILCS 15/5.4 new)
14     (Section scheduled to be repealed on January 1, 2017)
15     Sec. 5.4. Prescribing practices.
16     (a) Every prescription by a prescribing clinical
17 psychologist shall comply with all applicable State and federal
18 laws, be identified as issued by the psychologist as a
19 "prescribing clinical psychologist", and include the
20 prescriber's identification number assigned by the Board.
21     (b) Records of all prescriptions shall be maintained in
22 patient records.
23     (c) A prescribing clinical psychologist shall not delegate
24 the prescribing of drugs to any other person.

 

 

SB0648 - 7 - LRB095 06496 RAS 26597 b

1     (d) A prescribing clinical psychologist shall maintain an
2 ongoing collaborative relationship with the health care
3 practitioner who oversees the patient's general medical care to
4 ensure that necessary medical examinations are conducted, the
5 psychotropic medication is appropriate for the patient's
6 medical condition, and significant changes in the patient's
7 medical or psychological condition are discussed.
8     (e) For the purpose of this Section:
9     "Collaborative relationship" means a cooperative working
10 relationship between a prescribing clinical psychologist and a
11 health care practitioner in the provision of patient care,
12 including diagnosis and cooperation in the management and
13 delivery of physical and mental health care.
14     "Health care practitioner" means a physician, osteopathic
15 physician, or nurse practitioner.
 
16     (225 ILCS 15/5.5 new)
17     (Section scheduled to be repealed on January 1, 2017)
18     Sec. 5.5. Controlled substance prescriptive authority.
19     (a) When authorized to prescribe controlled substances,
20 each prescribing clinical psychologist shall file, in a timely
21 manner, any and all individual Drug Enforcement Agency (DEA)
22 registrations and Board-issued identification numbers with the
23 Board.
24     (b) The Board shall maintain current records of every
25 prescribing clinical psychologist, which shall include the DEA

 

 

SB0648 - 8 - LRB095 06496 RAS 26597 b

1 and Board-issued identification numbers of each prescribing
2 clinical psychologist.
 
3     (225 ILCS 15/5.6 new)
4     (Section scheduled to be repealed on January 1, 2017)
5     Sec. 5.6. Interaction with State Board of Pharmacy.
6     (a) The Clinical Psychologist Licensing and Disciplinary
7 Board shall transmit to the State Board of Pharmacy of the
8 Department of Financial and Professional Regulation an annual
9 list of prescribing clinical psychologists containing all of
10 the following information:
11         (1) the name of the prescribing clinical psychologist;
12         (2) the prescribing clinical psychologist's
13     identification number assigned by the Clinical
14     Psychologist Licensing and Disciplinary Board; and
15         (3) the effective dates of the prescribing clinical
16     psychologist's prescriptive authority.
17     (b) The Clinical Psychologist Licensing and Disciplinary
18 Board shall promptly forward to the State Board of Pharmacy the
19 names and titles of psychologists added to or deleted from the
20 annual list of prescribing clinical psychologists.
21     (c) The Clinical Psychologist Licensing and Disciplinary
22 Board shall, in a timely manner, notify the State Board of
23 Pharmacy of the termination, suspension, or reinstatement of a
24 psychologist's prescriptive authority.
 

 

 

SB0648 - 9 - LRB095 06496 RAS 26597 b

1     (225 ILCS 15/15)  (from Ch. 111, par. 5365)
2     (Section scheduled to be repealed on January 1, 2017)
3     Sec. 15. Disciplinary action; grounds. The Department may
4 refuse to issue, refuse to renew, suspend, or revoke any
5 license, or may place on probation, censure, reprimand, or take
6 other disciplinary action deemed appropriate by the
7 Department, including the imposition of fines not to exceed
8 $10,000 for each violation, with regard to any license issued
9 under the provisions of this Act for any one or a combination
10 of the following reasons:
11         (1) Conviction of, or entry of a plea of guilty or nolo
12     contendere to, any crime that is a felony under the laws of
13     the United States or any state or territory thereof or that
14     is a misdemeanor of which an essential element is
15     dishonesty, or any crime that is directly related to the
16     practice of the profession.
17         (2) Gross negligence in the rendering of clinical
18     psychological services.
19         (3) Using fraud or making any misrepresentation in
20     applying for a license or in passing the examination
21     provided for in this Act.
22         (4) Aiding or abetting or conspiring to aid or abet a
23     person, not a clinical psychologist licensed under this
24     Act, in representing himself or herself as so licensed or
25     in applying for a license under this Act.
26         (5) Violation of any provision of this Act or the rules

 

 

SB0648 - 10 - LRB095 06496 RAS 26597 b

1     promulgated thereunder.
2         (6) Professional connection or association with any
3     person, firm, association, partnership or corporation
4     holding himself, herself, themselves, or itself out in any
5     manner contrary to this Act.
6         (7) Unethical, unauthorized or unprofessional conduct
7     as defined by rule. In establishing those rules, the
8     Department shall consider, though is not bound by, the
9     ethical standards for psychologists promulgated by
10     recognized national psychology associations.
11         (8) Aiding or assisting another person in violating any
12     provisions of this Act or the rules promulgated thereunder.
13         (9) Failing to provide, within 60 days, information in
14     response to a written request made by the Department.
15         (10) Habitual or excessive use or addiction to alcohol,
16     narcotics, stimulants, or any other chemical agent or drug
17     that results in a clinical psychologist's inability to
18     practice with reasonable judgment, skill or safety.
19         (11) Discipline by another state, territory, the
20     District of Columbia or foreign country, if at least one of
21     the grounds for the discipline is the same or substantially
22     equivalent to those set forth herein.
23         (12) Directly or indirectly giving or receiving from
24     any person, firm, corporation, association or partnership
25     any fee, commission, rebate or other form of compensation
26     for any professional service not actually or personally

 

 

SB0648 - 11 - LRB095 06496 RAS 26597 b

1     rendered.
2         (13) A finding by the Board that the licensee, after
3     having his or her license placed on probationary status has
4     violated the terms of probation.
5         (14) Willfully making or filing false records or
6     reports, including but not limited to, false records or
7     reports filed with State agencies or departments.
8         (15) Physical illness, including but not limited to,
9     deterioration through the aging process, mental illness or
10     disability that results in the inability to practice the
11     profession with reasonable judgment, skill and safety.
12         (16) Willfully failing to report an instance of
13     suspected child abuse or neglect as required by the Abused
14     and Neglected Child Reporting Act.
15         (17) Being named as a perpetrator in an indicated
16     report by the Department of Children and Family Services
17     pursuant to the Abused and Neglected Child Reporting Act,
18     and upon proof by clear and convincing evidence that the
19     licensee has caused a child to be an abused child or
20     neglected child as defined in the Abused and Neglected
21     Child Reporting Act.
22         (18) Violation of the Health Care Worker Self-Referral
23     Act.
24         (19) Making a material misstatement in furnishing
25     information to the Department, any other State or federal
26     agency, or any other entity.

 

 

SB0648 - 12 - LRB095 06496 RAS 26597 b

1         (20) Failing to report to the Department any adverse
2     judgment, settlement, or award arising from a liability
3     claim related to an act or conduct similar to an act or
4     conduct that would constitute grounds for action as set
5     forth in this Section.
6         (21) Failing to report to the Department any adverse
7     final action taken against a licensee or applicant by
8     another licensing jurisdiction, including any other state
9     or territory of the United States or any foreign state or
10     country, or any peer review body, health care institution,
11     professional society or association related to the
12     profession, governmental agency, law enforcement agency,
13     or court for an act or conduct similar to an act or conduct
14     that would constitute grounds for disciplinary action as
15     set forth in this Section.
16     The entry of an order by any circuit court establishing
17 that any person holding a license under this Act is subject to
18 involuntary admission or judicial admission as provided for in
19 the Mental Health and Developmental Disabilities Code,
20 operates as an automatic suspension of that license. That
21 person may have his or her license restored only upon the
22 determination by a circuit court that the patient is no longer
23 subject to involuntary admission or judicial admission and the
24 issuance of an order so finding and discharging the patient and
25 upon the Board's recommendation to the Department that the
26 license be restored. Where the circumstances so indicate, the

 

 

SB0648 - 13 - LRB095 06496 RAS 26597 b

1 Board may recommend to the Department that it require an
2 examination prior to restoring any license so automatically
3 suspended.
4     The Department may refuse to issue or may suspend the
5 license of any person who fails to file a return, or to pay the
6 tax, penalty or interest shown in a filed return, or to pay any
7 final assessment of the tax penalty or interest, as required by
8 any tax Act administered by the Illinois Department of Revenue,
9 until such time as the requirements of any such tax Act are
10 satisfied.
11     In enforcing this Section, the Board upon a showing of a
12 possible violation may compel any person licensed to practice
13 under this Act, or who has applied for licensure or
14 certification pursuant to this Act, to submit to a mental or
15 physical examination, or both, as required by and at the
16 expense of the Department. The examining physicians or clinical
17 psychologists shall be those specifically designated by the
18 Board. The Board or the Department may order the examining
19 physician or clinical psychologist to present testimony
20 concerning this mental or physical examination of the licensee
21 or applicant. No information shall be excluded by reason of any
22 common law or statutory privilege relating to communications
23 between the licensee or applicant and the examining physician
24 or clinical psychologist. The person to be examined may have,
25 at his or her own expense, another physician or clinical
26 psychologist of his or her choice present during all aspects of

 

 

SB0648 - 14 - LRB095 06496 RAS 26597 b

1 the examination. Failure of any person to submit to a mental or
2 physical examination, when directed, shall be grounds for
3 suspension of a license until the person submits to the
4 examination if the Board finds, after notice and hearing, that
5 the refusal to submit to the examination was without reasonable
6 cause.
7     If the Board finds a person unable to practice because of
8 the reasons set forth in this Section, the Board may require
9 that person to submit to care, counseling or treatment by
10 physicians or clinical psychologists approved or designated by
11 the Board, as a condition, term, or restriction for continued,
12 reinstated, or renewed licensure to practice; or, in lieu of
13 care, counseling or treatment, the Board may recommend to the
14 Department to file a complaint to immediately suspend, revoke
15 or otherwise discipline the license of the person. Any person
16 whose license was granted, continued, reinstated, renewed,
17 disciplined or supervised subject to such terms, conditions or
18 restrictions, and who fails to comply with such terms,
19 conditions or restrictions, shall be referred to the Secretary
20 for a determination as to whether the person shall have his or
21 her license suspended immediately, pending a hearing by the
22 Board.
23     In instances in which the Secretary immediately suspends a
24 person's license under this Section, a hearing on that person's
25 license must be convened by the Board within 15 days after the
26 suspension and completed without appreciable delay. The Board

 

 

SB0648 - 15 - LRB095 06496 RAS 26597 b

1 shall have the authority to review the subject person's record
2 of treatment and counseling regarding the impairment, to the
3 extent permitted by applicable federal statutes and
4 regulations safeguarding the confidentiality of medical
5 records.
6     A person licensed under this Act and affected under this
7 Section shall be afforded an opportunity to demonstrate to the
8 Board that he or she can resume practice in compliance with
9 acceptable and prevailing standards under the provisions of his
10 or her license.
11     (b) The Board shall prescribe, by rule, criteria for
12 disciplining, suspending, or revoking the prescriptive
13 authority of a prescribing clinical psychologist. The Board
14 shall have the power and duty to require remediation,
15 suspension, or revocation of a psychologist's prescriptive
16 authority for a specified period of time, determined at the
17 discretion of the Board and in accordance with State law.
18 (Source: P.A. 94-870, eff. 6-16-06.)
 
19     Section 10. The Nursing and Advanced Practice Nursing Act
20 is amended by changing Sections 5-10 and 5-15 as follows:
 
21     (225 ILCS 65/5-10)
22     (Section scheduled to be repealed on January 1, 2008)
23     Sec. 5-10. Definitions. Each of the following terms, when
24 used in this Act, shall have the meaning ascribed to it in this

 

 

SB0648 - 16 - LRB095 06496 RAS 26597 b

1 Section, except where the context clearly indicates otherwise:
2     (a) "Department" means the Department of Professional
3 Regulation.
4     (b) "Director" means the Director of Professional
5 Regulation.
6     (c) "Board" means the Board of Nursing appointed by the
7 Director.
8     (d) "Academic year" means the customary annual schedule of
9 courses at a college, university, or approved school,
10 customarily regarded as the school year as distinguished from
11 the calendar year.
12     (e) "Approved program of professional nursing education"
13 and "approved program of practical nursing education" are
14 programs of professional or practical nursing, respectively,
15 approved by the Department under the provisions of this Act.
16     (f) "Nursing Act Coordinator" means a registered
17 professional nurse appointed by the Director to carry out the
18 administrative policies of the Department.
19     (g) "Assistant Nursing Act Coordinator" means a registered
20 professional nurse appointed by the Director to assist in
21 carrying out the administrative policies of the Department.
22     (h) "Registered" is the equivalent of "licensed".
23     (i) "Practical nurse" or "licensed practical nurse" means a
24 person who is licensed as a practical nurse under this Act and
25 practices practical nursing as defined in paragraph (j) of this
26 Section. Only a practical nurse licensed under this Act is

 

 

SB0648 - 17 - LRB095 06496 RAS 26597 b

1 entitled to use the title "licensed practical nurse" and the
2 abbreviation "L.P.N.".
3     (j) "Practical nursing" means the performance of nursing
4 acts requiring the basic nursing knowledge, judgement, and
5 skill acquired by means of completion of an approved practical
6 nursing education program. Practical nursing includes
7 assisting in the nursing process as delegated by and under the
8 direction of a registered professional nurse. The practical
9 nurse may work under the direction of a licensed physician,
10 dentist, podiatrist, or other health care professional
11 determined by the Department.
12     (k) "Registered Nurse" or "Registered Professional Nurse"
13 means a person who is licensed as a professional nurse under
14 this Act and practices nursing as defined in paragraph (l) of
15 this Section. Only a registered nurse licensed under this Act
16 is entitled to use the titles "registered nurse" and
17 "registered professional nurse" and the abbreviation, "R.N.".
18     (l) "Registered professional nursing practice" includes
19 all nursing specialities and means the performance of any
20 nursing act based upon professional knowledge, judgment, and
21 skills acquired by means of completion of an approved
22 registered professional nursing education program. A
23 registered professional nurse provides nursing care
24 emphasizing the importance of the whole and the interdependence
25 of its parts through the nursing process to individuals,
26 groups, families, or communities, that includes but is not

 

 

SB0648 - 18 - LRB095 06496 RAS 26597 b

1 limited to: (1) the assessment of healthcare needs, nursing
2 diagnosis, planning, implementation, and nursing evaluation;
3 (2) the promotion, maintenance, and restoration of health; (3)
4 counseling, patient education, health education, and patient
5 advocacy; (4) the administration of medications and treatments
6 as prescribed by a physician licensed to practice medicine in
7 all of its branches, a licensed dentist, a licensed podiatrist,
8 prescribing clinical psychologist, or a licensed optometrist
9 or as prescribed by a physician assistant in accordance with
10 written guidelines required under the Physician Assistant
11 Practice Act of 1987 or by an advanced practice nurse in
12 accordance with a written collaborative agreement required
13 under the Nursing and Advanced Practice Nursing Act; (5) the
14 coordination and management of the nursing plan of care; (6)
15 the delegation to and supervision of individuals who assist the
16 registered professional nurse implementing the plan of care;
17 and (7) teaching and supervision of nursing students. The
18 foregoing shall not be deemed to include those acts of medical
19 diagnosis or prescription of therapeutic or corrective
20 measures that are properly performed only by physicians
21 licensed in the State of Illinois.
22     (m) "Current nursing practice update course" means a
23 planned nursing education curriculum approved by the
24 Department consisting of activities that have educational
25 objectives, instructional methods, content or subject matter,
26 clinical practice, and evaluation methods, related to basic

 

 

SB0648 - 19 - LRB095 06496 RAS 26597 b

1 review and updating content and specifically planned for those
2 nurses previously licensed in the United States or its
3 territories and preparing for reentry into nursing practice.
4     (n) "Professional assistance program for nurses" means a
5 professional assistance program that meets criteria
6 established by the Board of Nursing and approved by the
7 Director, which provides a non-disciplinary treatment approach
8 for nurses licensed under this Act whose ability to practice is
9 compromised by alcohol or chemical substance addiction.
10 (Source: P.A. 90-61, eff. 12-30-97; 90-248, eff. 1-1-98;
11 90-655, eff. 7-30-98; 90-742, eff. 8-13-98.)
 
12     Section 15. The Pharmacy Practice Act of 1987 is amended by
13 changing Sections 3 and 4 as follows:
 
14     (225 ILCS 85/3)  (from Ch. 111, par. 4123)
15     (Section scheduled to be repealed on January 1, 2008)
16     Sec. 3. Definitions. For the purpose of this Act, except
17 where otherwise limited therein:
18     (a) "Pharmacy" or "drugstore" means and includes every
19 store, shop, pharmacy department, or other place where
20 pharmaceutical care is provided by a pharmacist (1) where
21 drugs, medicines, or poisons are dispensed, sold or offered for
22 sale at retail, or displayed for sale at retail; or (2) where
23 prescriptions of physicians, dentists, veterinarians,
24 podiatrists, prescribing clinical psychologists, or

 

 

SB0648 - 20 - LRB095 06496 RAS 26597 b

1 therapeutically certified optometrists, within the limits of
2 their licenses, are compounded, filled, or dispensed; or (3)
3 which has upon it or displayed within it, or affixed to or used
4 in connection with it, a sign bearing the word or words
5 "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care",
6 "Apothecary", "Drugstore", "Medicine Store", "Prescriptions",
7 "Drugs", "Medicines", or any word or words of similar or like
8 import, either in the English language or any other language;
9 or (4) where the characteristic prescription sign (Rx) or
10 similar design is exhibited; or (5) any store, or shop, or
11 other place with respect to which any of the above words,
12 objects, signs or designs are used in any advertisement.
13     (b) "Drugs" means and includes (l) articles recognized in
14 the official United States Pharmacopoeia/National Formulary
15 (USP/NF), or any supplement thereto and being intended for and
16 having for their main use the diagnosis, cure, mitigation,
17 treatment or prevention of disease in man or other animals, as
18 approved by the United States Food and Drug Administration, but
19 does not include devices or their components, parts, or
20 accessories; and (2) all other articles intended for and having
21 for their main use the diagnosis, cure, mitigation, treatment
22 or prevention of disease in man or other animals, as approved
23 by the United States Food and Drug Administration, but does not
24 include devices or their components, parts, or accessories; and
25 (3) articles (other than food) having for their main use and
26 intended to affect the structure or any function of the body of

 

 

SB0648 - 21 - LRB095 06496 RAS 26597 b

1 man or other animals; and (4) articles having for their main
2 use and intended for use as a component or any articles
3 specified in clause (l), (2) or (3); but does not include
4 devices or their components, parts or accessories.
5     (c) "Medicines" means and includes all drugs intended for
6 human or veterinary use approved by the United States Food and
7 Drug Administration.
8     (d) "Practice of pharmacy" means the provision of
9 pharmaceutical care to patients as determined by the
10 pharmacist's professional judgment in the following areas,
11 which may include but are not limited to (1) patient
12 counseling, (2) interpretation and assisting in the monitoring
13 of appropriate drug use and prospective drug utilization
14 review, (3) providing information on the therapeutic values,
15 reactions, drug interactions, side effects, uses, selection of
16 medications and medical devices, and outcome of drug therapy,
17 (4) participation in drug selection, drug monitoring, drug
18 utilization review, evaluation, administration,
19 interpretation, application of pharmacokinetic and laboratory
20 data to design safe and effective drug regimens, (5) drug
21 research (clinical and scientific), and (6) compounding and
22 dispensing of drugs and medical devices.
23     (e) "Prescription" means and includes any written, oral,
24 facsimile, or electronically transmitted order for drugs or
25 medical devices, issued by a physician licensed to practice
26 medicine in all its branches, dentist, veterinarian,

 

 

SB0648 - 22 - LRB095 06496 RAS 26597 b

1 prescribing clinical psychologist, or podiatrist, or
2 therapeutically certified optometrist, within the limits of
3 their licenses, by a physician assistant in accordance with
4 subsection (f) of Section 4, or by an advanced practice nurse
5 in accordance with subsection (g) of Section 4, containing the
6 following: (l) name of the patient; (2) date when prescription
7 was issued; (3) name and strength of drug or description of the
8 medical device prescribed; and (4) quantity, (5) directions for
9 use, (6) prescriber's name, address and signature, and (7) DEA
10 number where required, for controlled substances. DEA numbers
11 shall not be required on inpatient drug orders.
12     (f) "Person" means and includes a natural person,
13 copartnership, association, corporation, government entity, or
14 any other legal entity.
15     (g) "Department" means the Department of Professional
16 Regulation.
17     (h) "Board of Pharmacy" or "Board" means the State Board of
18 Pharmacy of the Department of Professional Regulation.
19     (i) "Director" means the Director of Professional
20 Regulation.
21     (j) "Drug product selection" means the interchange for a
22 prescribed pharmaceutical product in accordance with Section
23 25 of this Act and Section 3.14 of the Illinois Food, Drug and
24 Cosmetic Act.
25     (k) "Inpatient drug order" means an order issued by an
26 authorized prescriber for a resident or patient of a facility

 

 

SB0648 - 23 - LRB095 06496 RAS 26597 b

1 licensed under the Nursing Home Care Act or the Hospital
2 Licensing Act, or "An Act in relation to the founding and
3 operation of the University of Illinois Hospital and the
4 conduct of University of Illinois health care programs",
5 approved July 3, 1931, as amended, or a facility which is
6 operated by the Department of Human Services (as successor to
7 the Department of Mental Health and Developmental
8 Disabilities) or the Department of Corrections.
9     (k-5) "Pharmacist" means an individual health care
10 professional and provider currently licensed by this State to
11 engage in the practice of pharmacy.
12     (l) "Pharmacist in charge" means the licensed pharmacist
13 whose name appears on a pharmacy license and who is responsible
14 for all aspects of the operation related to the practice of
15 pharmacy.
16     (m) "Dispense" means the delivery of drugs and medical
17 devices, in accordance with applicable State and federal laws
18 and regulations, to the patient or the patient's representative
19 authorized to receive these products, including the
20 preparation, compounding, packaging, and labeling necessary
21 for delivery, computer entry, and verification of medication
22 orders and prescriptions, and any recommending or advising
23 concerning the contents and therapeutic values and uses
24 thereof. "Dispense" does not mean the physical delivery to a
25 patient or a patient's representative in a home or institution
26 by a designee of a pharmacist or by common carrier. "Dispense"

 

 

SB0648 - 24 - LRB095 06496 RAS 26597 b

1 also does not mean the physical delivery of a drug or medical
2 device to a patient or patient's representative by a
3 pharmacist's designee within a pharmacy or drugstore while the
4 pharmacist is on duty and the pharmacy is open.
5     (n) "Mail-order pharmacy" means a pharmacy that is located
6 in a state of the United States, other than Illinois, that
7 delivers, dispenses or distributes, through the United States
8 Postal Service or other common carrier, to Illinois residents,
9 any substance which requires a prescription.
10     (o) "Compounding" means the preparation, mixing,
11 assembling, packaging, or labeling of a drug or medical device:
12 (1) as the result of a practitioner's prescription drug order
13 or initiative that is dispensed pursuant to a prescription in
14 the course of professional practice; or (2) for the purpose of,
15 or incident to, research, teaching, or chemical analysis; or
16 (3) in anticipation of prescription drug orders based on
17 routine, regularly observed prescribing patterns.
18     (p) "Confidential information" means information,
19 maintained by the pharmacist in the patient's records, released
20 only (i) to the patient or, as the patient directs, to other
21 practitioners and other pharmacists or (ii) to any other person
22 authorized by law to receive the information.
23     (q) "Prospective drug review" or "drug utilization
24 evaluation" means a screening for potential drug therapy
25 problems due to therapeutic duplication, drug-disease
26 contraindications, drug-drug interactions (including serious

 

 

SB0648 - 25 - LRB095 06496 RAS 26597 b

1 interactions with nonprescription or over-the-counter drugs),
2 drug-food interactions, incorrect drug dosage or duration of
3 drug treatment, drug-allergy interactions, and clinical abuse
4 or misuse.
5     (r) "Patient counseling" means the communication between a
6 pharmacist or a student pharmacist under the direct supervision
7 of a pharmacist and a patient or the patient's representative
8 about the patient's medication or device for the purpose of
9 optimizing proper use of prescription medications or devices.
10 The offer to counsel by the pharmacist or the pharmacist's
11 designee, and subsequent patient counseling by the pharmacist
12 or student pharmacist, shall be made in a face-to-face
13 communication with the patient or patient's representative
14 unless, in the professional judgment of the pharmacist, a
15 face-to-face communication is deemed inappropriate or
16 unnecessary. In that instance, the offer to counsel or patient
17 counseling may be made in a written communication, by
18 telephone, or in a manner determined by the pharmacist to be
19 appropriate.
20     (s) "Patient profiles" or "patient drug therapy record"
21 means the obtaining, recording, and maintenance of patient
22 prescription information, including prescriptions for
23 controlled substances, and personal information.
24     (t) "Pharmaceutical care" includes, but is not limited to,
25 the act of monitoring drug use and other patient care services
26 intended to achieve outcomes that improve the patient's quality

 

 

SB0648 - 26 - LRB095 06496 RAS 26597 b

1 of life but shall not include the sale of over-the-counter
2 drugs by a seller of goods and services who does not dispense
3 prescription drugs.
4     (u) "Medical device" means an instrument, apparatus,
5 implement, machine, contrivance, implant, in vitro reagent, or
6 other similar or related article, including any component part
7 or accessory, required under federal law to bear the label
8 "Caution: Federal law requires dispensing by or on the order of
9 a physician". A seller of goods and services who, only for the
10 purpose of retail sales, compounds, sells, rents, or leases
11 medical devices shall not, by reasons thereof, be required to
12 be a licensed pharmacy.
13     (v) "Unique identifier" means an electronic signature,
14 handwritten signature or initials, thumb print, or other
15 acceptable individual biometric or electronic identification
16 process as approved by the Department.
17     (w) "Current usual and customary retail price" means the
18 actual price that a pharmacy charges a retail purchaser.
19 (Source: P.A. 93-571, eff. 8-20-03; 93-1075, eff. 1-18-05;
20 94-459, eff. 1-1-06.)
 
21     (225 ILCS 85/4)  (from Ch. 111, par. 4124)
22     (Section scheduled to be repealed on January 1, 2008)
23     Sec. 4. Exemptions. Nothing contained in any Section of
24 this Act shall apply to, or in any manner interfere with:
25     (a) the lawful practice of any physician licensed to

 

 

SB0648 - 27 - LRB095 06496 RAS 26597 b

1 practice medicine in all of its branches, dentist, podiatrist,
2 veterinarian, prescribing clinical psychologist, or
3 therapeutically or diagnostically certified optometrist within
4 the limits of his or her license, or prevent him or her from
5 supplying to his or her bona fide patients such drugs,
6 medicines, or poisons as may seem to him appropriate;
7     (b) the sale of compressed gases;
8     (c) the sale of patent or proprietary medicines and
9 household remedies when sold in original and unbroken packages
10 only, if such patent or proprietary medicines and household
11 remedies be properly and adequately labeled as to content and
12 usage and generally considered and accepted as harmless and
13 nonpoisonous when used according to the directions on the
14 label, and also do not contain opium or coca leaves, or any
15 compound, salt or derivative thereof, or any drug which,
16 according to the latest editions of the following authoritative
17 pharmaceutical treatises and standards, namely, The United
18 States Pharmacopoeia/National Formulary (USP/NF), the United
19 States Dispensatory, and the Accepted Dental Remedies of the
20 Council of Dental Therapeutics of the American Dental
21 Association or any or either of them, in use on the effective
22 date of this Act, or according to the existing provisions of
23 the Federal Food, Drug, and Cosmetic Act and Regulations of the
24 Department of Health and Human Services, Food and Drug
25 Administration, promulgated thereunder now in effect, is
26 designated, described or considered as a narcotic, hypnotic,

 

 

SB0648 - 28 - LRB095 06496 RAS 26597 b

1 habit forming, dangerous, or poisonous drug;
2     (d) the sale of poultry and livestock remedies in original
3 and unbroken packages only, labeled for poultry and livestock
4 medication;
5     (e) the sale of poisonous substances or mixture of
6 poisonous substances, in unbroken packages, for nonmedicinal
7 use in the arts or industries or for insecticide purposes;
8 provided, they are properly and adequately labeled as to
9 content and such nonmedicinal usage, in conformity with the
10 provisions of all applicable federal, state and local laws and
11 regulations promulgated thereunder now in effect relating
12 thereto and governing the same, and those which are required
13 under such applicable laws and regulations to be labeled with
14 the word "Poison", are also labeled with the word "Poison"
15 printed thereon in prominent type and the name of a readily
16 obtainable antidote with directions for its administration;
17     (f) the delegation of limited prescriptive authority by a
18 physician licensed to practice medicine in all its branches to
19 a physician assistant under Section 7.5 of the Physician
20 Assistant Practice Act of 1987. This delegated authority may
21 but is not required to include prescription of Schedule III,
22 IV, or V controlled substances, as defined in Article II of the
23 Illinois Controlled Substances Act, in accordance with written
24 guidelines under Section 7.5 of the Physician Assistant
25 Practice Act of 1987; and
26     (g) The delegation of limited prescriptive authority by a

 

 

SB0648 - 29 - LRB095 06496 RAS 26597 b

1 physician licensed to practice medicine in all its branches to
2 an advanced practice nurse in accordance with a written
3 collaborative agreement under Sections 15-15 and 15-20 of the
4 Nursing and Advanced Practice Nursing Act. This delegated
5 authority may but is not required to include the prescription
6 of Schedule III, IV, or V controlled substances as defined in
7 Article II of the Illinois Controlled Substances Act.
8 (Source: P.A. 90-116, eff. 7-14-97; 90-253, eff. 7-29-97;
9 90-655, eff. 7-30-98; 90-742, eff. 8-13-98.)
 
10     Section 20. The Illinois Controlled Substances Act is
11 amended by changing Section 102 as follows:
 
12     (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
13     Sec. 102. Definitions. As used in this Act, unless the
14 context otherwise requires:
15     (a) "Addict" means any person who habitually uses any drug,
16 chemical, substance or dangerous drug other than alcohol so as
17 to endanger the public morals, health, safety or welfare or who
18 is so far addicted to the use of a dangerous drug or controlled
19 substance other than alcohol as to have lost the power of self
20 control with reference to his addiction.
21     (b) "Administer" means the direct application of a
22 controlled substance, whether by injection, inhalation,
23 ingestion, or any other means, to the body of a patient,
24 research subject, or animal (as defined by the Humane

 

 

SB0648 - 30 - LRB095 06496 RAS 26597 b

1 Euthanasia in Animal Shelters Act) by:
2         (1) a practitioner (or, in his presence, by his
3     authorized agent),
4         (2) the patient or research subject at the lawful
5     direction of the practitioner, or
6         (3) a euthanasia technician as defined by the Humane
7     Euthanasia in Animal Shelters Act.
8     (c) "Agent" means an authorized person who acts on behalf
9 of or at the direction of a manufacturer, distributor, or
10 dispenser. It does not include a common or contract carrier,
11 public warehouseman or employee of the carrier or warehouseman.
12     (c-1) "Anabolic Steroids" means any drug or hormonal
13 substance, chemically and pharmacologically related to
14 testosterone (other than estrogens, progestins, and
15 corticosteroids) that promotes muscle growth, and includes:
16             (i) boldenone,
17             (ii) chlorotestosterone,
18             (iii) chostebol,
19             (iv) dehydrochlormethyltestosterone,
20             (v) dihydrotestosterone,
21             (vi) drostanolone,
22             (vii) ethylestrenol,
23             (viii) fluoxymesterone,
24             (ix) formebulone,
25             (x) mesterolone,
26             (xi) methandienone,

 

 

SB0648 - 31 - LRB095 06496 RAS 26597 b

1             (xii) methandranone,
2             (xiii) methandriol,
3             (xiv) methandrostenolone,
4             (xv) methenolone,
5             (xvi) methyltestosterone,
6             (xvii) mibolerone,
7             (xviii) nandrolone,
8             (xix) norethandrolone,
9             (xx) oxandrolone,
10             (xxi) oxymesterone,
11             (xxii) oxymetholone,
12             (xxiii) stanolone,
13             (xxiv) stanozolol,
14             (xxv) testolactone,
15             (xxvi) testosterone,
16             (xxvii) trenbolone, and
17             (xxviii) any salt, ester, or isomer of a drug or
18         substance described or listed in this paragraph, if
19         that salt, ester, or isomer promotes muscle growth.
20     Any person who is otherwise lawfully in possession of an
21 anabolic steroid, or who otherwise lawfully manufactures,
22 distributes, dispenses, delivers, or possesses with intent to
23 deliver an anabolic steroid, which anabolic steroid is
24 expressly intended for and lawfully allowed to be administered
25 through implants to livestock or other nonhuman species, and
26 which is approved by the Secretary of Health and Human Services

 

 

SB0648 - 32 - LRB095 06496 RAS 26597 b

1 for such administration, and which the person intends to
2 administer or have administered through such implants, shall
3 not be considered to be in unauthorized possession or to
4 unlawfully manufacture, distribute, dispense, deliver, or
5 possess with intent to deliver such anabolic steroid for
6 purposes of this Act.
7     (d) "Administration" means the Drug Enforcement
8 Administration, United States Department of Justice, or its
9 successor agency.
10     (e) "Control" means to add a drug or other substance, or
11 immediate precursor, to a Schedule under Article II of this Act
12 whether by transfer from another Schedule or otherwise.
13     (f) "Controlled Substance" means a drug, substance, or
14 immediate precursor in the Schedules of Article II of this Act.
15     (g) "Counterfeit substance" means a controlled substance,
16 which, or the container or labeling of which, without
17 authorization bears the trademark, trade name, or other
18 identifying mark, imprint, number or device, or any likeness
19 thereof, of a manufacturer, distributor, or dispenser other
20 than the person who in fact manufactured, distributed, or
21 dispensed the substance.
22     (h) "Deliver" or "delivery" means the actual, constructive
23 or attempted transfer of possession of a controlled substance,
24 with or without consideration, whether or not there is an
25 agency relationship.
26     (i) "Department" means the Illinois Department of Human

 

 

SB0648 - 33 - LRB095 06496 RAS 26597 b

1 Services (as successor to the Department of Alcoholism and
2 Substance Abuse) or its successor agency.
3     (j) "Department of State Police" means the Department of
4 State Police of the State of Illinois or its successor agency.
5     (k) "Department of Corrections" means the Department of
6 Corrections of the State of Illinois or its successor agency.
7     (l) "Department of Professional Regulation" means the
8 Department of Professional Regulation of the State of Illinois
9 or its successor agency.
10     (m) "Depressant" or "stimulant substance" means:
11         (1) a drug which contains any quantity of (i)
12     barbituric acid or any of the salts of barbituric acid
13     which has been designated as habit forming under section
14     502 (d) of the Federal Food, Drug, and Cosmetic Act (21
15     U.S.C. 352 (d)); or
16         (2) a drug which contains any quantity of (i)
17     amphetamine or methamphetamine and any of their optical
18     isomers; (ii) any salt of amphetamine or methamphetamine or
19     any salt of an optical isomer of amphetamine; or (iii) any
20     substance which the Department, after investigation, has
21     found to be, and by rule designated as, habit forming
22     because of its depressant or stimulant effect on the
23     central nervous system; or
24         (3) lysergic acid diethylamide; or
25         (4) any drug which contains any quantity of a substance
26     which the Department, after investigation, has found to

 

 

SB0648 - 34 - LRB095 06496 RAS 26597 b

1     have, and by rule designated as having, a potential for
2     abuse because of its depressant or stimulant effect on the
3     central nervous system or its hallucinogenic effect.
4     (n) (Blank).
5     (o) "Director" means the Director of the Department of
6 State Police or the Department of Professional Regulation or
7 his designated agents.
8     (p) "Dispense" means to deliver a controlled substance to
9 an ultimate user or research subject by or pursuant to the
10 lawful order of a prescriber, including the prescribing,
11 administering, packaging, labeling, or compounding necessary
12 to prepare the substance for that delivery.
13     (q) "Dispenser" means a practitioner who dispenses.
14     (r) "Distribute" means to deliver, other than by
15 administering or dispensing, a controlled substance.
16     (s) "Distributor" means a person who distributes.
17     (t) "Drug" means (1) substances recognized as drugs in the
18 official United States Pharmacopoeia, Official Homeopathic
19 Pharmacopoeia of the United States, or official National
20 Formulary, or any supplement to any of them; (2) substances
21 intended for use in diagnosis, cure, mitigation, treatment, or
22 prevention of disease in man or animals; (3) substances (other
23 than food) intended to affect the structure of any function of
24 the body of man or animals and (4) substances intended for use
25 as a component of any article specified in clause (1), (2), or
26 (3) of this subsection. It does not include devices or their

 

 

SB0648 - 35 - LRB095 06496 RAS 26597 b

1 components, parts, or accessories.
2     (t-5) "Euthanasia agency" means an entity certified by the
3 Department of Professional Regulation for the purpose of animal
4 euthanasia that holds an animal control facility license or
5 animal shelter license under the Animal Welfare Act. A
6 euthanasia agency is authorized to purchase, store, possess,
7 and utilize Schedule II nonnarcotic and Schedule III
8 nonnarcotic drugs for the sole purpose of animal euthanasia.
9     (t-10) "Euthanasia drugs" means Schedule II or Schedule III
10 substances (nonnarcotic controlled substances) that are used
11 by a euthanasia agency for the purpose of animal euthanasia.
12     (u) "Good faith" means the prescribing or dispensing of a
13 controlled substance by a practitioner in the regular course of
14 professional treatment to or for any person who is under his
15 treatment for a pathology or condition other than that
16 individual's physical or psychological dependence upon or
17 addiction to a controlled substance, except as provided herein:
18 and application of the term to a pharmacist shall mean the
19 dispensing of a controlled substance pursuant to the
20 prescriber's order which in the professional judgment of the
21 pharmacist is lawful. The pharmacist shall be guided by
22 accepted professional standards including, but not limited to
23 the following, in making the judgment:
24         (1) lack of consistency of doctor-patient
25     relationship,
26         (2) frequency of prescriptions for same drug by one

 

 

SB0648 - 36 - LRB095 06496 RAS 26597 b

1     prescriber for large numbers of patients,
2         (3) quantities beyond those normally prescribed,
3         (4) unusual dosages,
4         (5) unusual geographic distances between patient,
5     pharmacist and prescriber,
6         (6) consistent prescribing of habit-forming drugs.
7     (u-1) "Home infusion services" means services provided by a
8 pharmacy in compounding solutions for direct administration to
9 a patient in a private residence, long-term care facility, or
10 hospice setting by means of parenteral, intravenous,
11 intramuscular, subcutaneous, or intraspinal infusion.
12     (v) "Immediate precursor" means a substance:
13         (1) which the Department has found to be and by rule
14     designated as being a principal compound used, or produced
15     primarily for use, in the manufacture of a controlled
16     substance;
17         (2) which is an immediate chemical intermediary used or
18     likely to be used in the manufacture of such controlled
19     substance; and
20         (3) the control of which is necessary to prevent,
21     curtail or limit the manufacture of such controlled
22     substance.
23     (w) "Instructional activities" means the acts of teaching,
24 educating or instructing by practitioners using controlled
25 substances within educational facilities approved by the State
26 Board of Education or its successor agency.

 

 

SB0648 - 37 - LRB095 06496 RAS 26597 b

1     (x) "Local authorities" means a duly organized State,
2 County or Municipal peace unit or police force.
3     (y) "Look-alike substance" means a substance, other than a
4 controlled substance which (1) by overall dosage unit
5 appearance, including shape, color, size, markings or lack
6 thereof, taste, consistency, or any other identifying physical
7 characteristic of the substance, would lead a reasonable person
8 to believe that the substance is a controlled substance, or (2)
9 is expressly or impliedly represented to be a controlled
10 substance or is distributed under circumstances which would
11 lead a reasonable person to believe that the substance is a
12 controlled substance. For the purpose of determining whether
13 the representations made or the circumstances of the
14 distribution would lead a reasonable person to believe the
15 substance to be a controlled substance under this clause (2) of
16 subsection (y), the court or other authority may consider the
17 following factors in addition to any other factor that may be
18 relevant:
19         (a) statements made by the owner or person in control
20     of the substance concerning its nature, use or effect;
21         (b) statements made to the buyer or recipient that the
22     substance may be resold for profit;
23         (c) whether the substance is packaged in a manner
24     normally used for the illegal distribution of controlled
25     substances;
26         (d) whether the distribution or attempted distribution

 

 

SB0648 - 38 - LRB095 06496 RAS 26597 b

1     included an exchange of or demand for money or other
2     property as consideration, and whether the amount of the
3     consideration was substantially greater than the
4     reasonable retail market value of the substance.
5     Clause (1) of this subsection (y) shall not apply to a
6 noncontrolled substance in its finished dosage form that was
7 initially introduced into commerce prior to the initial
8 introduction into commerce of a controlled substance in its
9 finished dosage form which it may substantially resemble.
10     Nothing in this subsection (y) prohibits the dispensing or
11 distributing of noncontrolled substances by persons authorized
12 to dispense and distribute controlled substances under this
13 Act, provided that such action would be deemed to be carried
14 out in good faith under subsection (u) if the substances
15 involved were controlled substances.
16     Nothing in this subsection (y) or in this Act prohibits the
17 manufacture, preparation, propagation, compounding,
18 processing, packaging, advertising or distribution of a drug or
19 drugs by any person registered pursuant to Section 510 of the
20 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
21     (y-1) "Mail-order pharmacy" means a pharmacy that is
22 located in a state of the United States, other than Illinois,
23 that delivers, dispenses or distributes, through the United
24 States Postal Service or other common carrier, to Illinois
25 residents, any substance which requires a prescription.
26     (z) "Manufacture" means the production, preparation,

 

 

SB0648 - 39 - LRB095 06496 RAS 26597 b

1 propagation, compounding, conversion or processing of a
2 controlled substance other than methamphetamine, either
3 directly or indirectly, by extraction from substances of
4 natural origin, or independently by means of chemical
5 synthesis, or by a combination of extraction and chemical
6 synthesis, and includes any packaging or repackaging of the
7 substance or labeling of its container, except that this term
8 does not include:
9         (1) by an ultimate user, the preparation or compounding
10     of a controlled substance for his own use; or
11         (2) by a practitioner, or his authorized agent under
12     his supervision, the preparation, compounding, packaging,
13     or labeling of a controlled substance:
14             (a) as an incident to his administering or
15         dispensing of a controlled substance in the course of
16         his professional practice; or
17             (b) as an incident to lawful research, teaching or
18         chemical analysis and not for sale.
19     (z-1) (Blank).
20     (aa) "Narcotic drug" means any of the following, whether
21 produced directly or indirectly by extraction from substances
22 of natural origin, or independently by means of chemical
23 synthesis, or by a combination of extraction and chemical
24 synthesis:
25         (1) opium and opiate, and any salt, compound,
26     derivative, or preparation of opium or opiate;

 

 

SB0648 - 40 - LRB095 06496 RAS 26597 b

1         (2) any salt, compound, isomer, derivative, or
2     preparation thereof which is chemically equivalent or
3     identical with any of the substances referred to in clause
4     (1), but not including the isoquinoline alkaloids of opium;
5         (3) opium poppy and poppy straw;
6         (4) coca leaves and any salts, compound, isomer, salt
7     of an isomer, derivative, or preparation of coca leaves
8     including cocaine or ecgonine, and any salt, compound,
9     isomer, derivative, or preparation thereof which is
10     chemically equivalent or identical with any of these
11     substances, but not including decocainized coca leaves or
12     extractions of coca leaves which do not contain cocaine or
13     ecgonine (for the purpose of this paragraph, the term
14     "isomer" includes optical, positional and geometric
15     isomers).
16     (bb) "Nurse" means a registered nurse licensed under the
17 Nursing and Advanced Practice Nursing Act.
18     (cc) (Blank).
19     (dd) "Opiate" means any substance having an addiction
20 forming or addiction sustaining liability similar to morphine
21 or being capable of conversion into a drug having addiction
22 forming or addiction sustaining liability.
23     (ee) "Opium poppy" means the plant of the species Papaver
24 somniferum L., except its seeds.
25     (ff) "Parole and Pardon Board" means the Parole and Pardon
26 Board of the State of Illinois or its successor agency.

 

 

SB0648 - 41 - LRB095 06496 RAS 26597 b

1     (gg) "Person" means any individual, corporation,
2 mail-order pharmacy, government or governmental subdivision or
3 agency, business trust, estate, trust, partnership or
4 association, or any other entity.
5     (hh) "Pharmacist" means any person who holds a certificate
6 of registration as a registered pharmacist, a local registered
7 pharmacist or a registered assistant pharmacist under the
8 Pharmacy Practice Act of 1987.
9     (ii) "Pharmacy" means any store, ship or other place in
10 which pharmacy is authorized to be practiced under the Pharmacy
11 Practice Act of 1987.
12     (jj) "Poppy straw" means all parts, except the seeds, of
13 the opium poppy, after mowing.
14     (kk) "Practitioner" means a physician licensed to practice
15 medicine in all its branches, dentist, podiatrist, prescribing
16 clinical psychologist, veterinarian, scientific investigator,
17 pharmacist, physician assistant, advanced practice nurse,
18 licensed practical nurse, registered nurse, hospital,
19 laboratory, or pharmacy, or other person licensed, registered,
20 or otherwise lawfully permitted by the United States or this
21 State to distribute, dispense, conduct research with respect
22 to, administer or use in teaching or chemical analysis, a
23 controlled substance in the course of professional practice or
24 research.
25     (ll) "Pre-printed prescription" means a written
26 prescription upon which the designated drug has been indicated

 

 

SB0648 - 42 - LRB095 06496 RAS 26597 b

1 prior to the time of issuance.
2     (mm) "Prescriber" means a physician licensed to practice
3 medicine in all its branches, dentist, podiatrist, prescribing
4 clinical psychologist, or veterinarian who issues a
5 prescription, a physician assistant who issues a prescription
6 for a Schedule III, IV, or V controlled substance in accordance
7 with Section 303.05 and the written guidelines required under
8 Section 7.5 of the Physician Assistant Practice Act of 1987, or
9 an advanced practice nurse with prescriptive authority in
10 accordance with Section 303.05 and a written collaborative
11 agreement under Sections 15-15 and 15-20 of the Nursing and
12 Advanced Practice Nursing Act.
13     (nn) "Prescription" means a lawful written, facsimile, or
14 verbal order of a physician licensed to practice medicine in
15 all its branches, dentist, podiatrist, prescribing clinical
16 psychologist, or veterinarian for any controlled substance, of
17 a physician assistant for a Schedule III, IV, or V controlled
18 substance in accordance with Section 303.05 and the written
19 guidelines required under Section 7.5 of the Physician
20 Assistant Practice Act of 1987, or of an advanced practice
21 nurse who issues a prescription for a Schedule III, IV, or V
22 controlled substance in accordance with Section 303.05 and a
23 written collaborative agreement under Sections 15-15 and 15-20
24 of the Nursing and Advanced Practice Nursing Act.
25     (oo) "Production" or "produce" means manufacture,
26 planting, cultivating, growing, or harvesting of a controlled

 

 

SB0648 - 43 - LRB095 06496 RAS 26597 b

1 substance other than methamphetamine.
2     (pp) "Registrant" means every person who is required to
3 register under Section 302 of this Act.
4     (qq) "Registry number" means the number assigned to each
5 person authorized to handle controlled substances under the
6 laws of the United States and of this State.
7     (rr) "State" includes the State of Illinois and any state,
8 district, commonwealth, territory, insular possession thereof,
9 and any area subject to the legal authority of the United
10 States of America.
11     (ss) "Ultimate user" means a person who lawfully possesses
12 a controlled substance for his own use or for the use of a
13 member of his household or for administering to an animal owned
14 by him or by a member of his household.
15 (Source: P.A. 93-596, eff. 8-26-03; 93-626, eff. 12-23-03;
16 94-556, eff. 9-11-05.)